Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$779.60
+0.0%
$773.61
$677.09
$972.53
$738.85B0.43.65 million shs1.45 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$298.49
-0.6%
$291.28
$200.63
$377.46
$6.63B-1.05358,338 shs108,674 shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$48.34
-0.6%
$44.83
$37.63
$49.30
$10.75B0.681.20 million shs770,537 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$28.16
+1.6%
$27.42
$18.92
$81.73
$3.16B0.624.02 million shs2.38 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+0.44%+1.25%+7.97%-14.76%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-0.75%+7.28%-3.88%+7.93%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%+1.21%+6.29%+19.87%+20.98%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+6.18%+1.19%+32.33%-45.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9885 of 5 stars
4.44.03.34.03.11.71.9
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.0896 of 5 stars
3.40.00.04.62.23.30.6
Qiagen N.V. stock logo
QGEN
Qiagen
4.045 of 5 stars
1.25.01.74.52.71.71.3
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.2736 of 5 stars
4.51.00.04.71.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6129.76% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.89
Moderate Buy$420.6340.92% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.30
Hold$49.402.19% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15209.50% Upside

Current Analyst Ratings Breakdown

Latest VKTX, MDGL, LLY, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/24/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$441.00 ➝ $458.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$422.00 ➝ $460.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$394.00 ➝ $420.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.40$14.22 per share54.84$15.03 per share51.87
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$180.13M36.79N/AN/A$34.59 per share8.63
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.43$3.21 per share15.08$16.05 per share3.01
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.4325.051.1422.67%85.51%15.74%8/7/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$0.40121.2019.652.464.68%14.61%8.80%7/30/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest VKTX, MDGL, LLY, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60N/AN/AN/A$523.97 millionN/A
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
5/7/2025Q1 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%N/A62.50%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, MDGL, LLY, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.17
5.91
5.58
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
21.50%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.41 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million17.43 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...
VKTX Viking Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$779.60 +0.32 (+0.04%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$780.97 +1.38 (+0.18%)
As of 08:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$298.48 0.00 (0.00%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$48.34 -0.30 (-0.62%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$47.99 -0.35 (-0.72%)
As of 08:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$28.16 +0.44 (+1.59%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$28.04 -0.12 (-0.43%)
As of 08:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.